Contrasting Genmab A/S (NASDAQ:GMAB) and Organigram (NASDAQ:OGI)

Organigram (NASDAQ:OGI – Get Free Report) and Genmab A/S (NASDAQ:GMAB – Get Free Report) are both healthcare companies, but which is the better business? We’ll compare the two companies based on their earnings strength, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

return

This table compares Organigram and Genmab A/S’s net margins, return on equity and return on assets.

Institutional and privileged ownership

34.6% of Organigram shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 0.1% of Organigram shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, big money managers and endowments believe a company will outperform the market over the long term.

Rating and Earnings

This table compares Organigram and Genmab A/S’s revenue, earnings per share (EPS) and valuation.

Genmab A/S has higher revenue and earnings than Organigram. Organigram is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Risk and volatility

Organigram has a beta of 1.06, meaning its share price is 6% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.97, meaning its share price is 3% less volatile than the S&P 500.

Analyst ratings

This is a summary of recent ratings and recommendations for Organigram and Genmab A/S, as reported by MarketBeat.

Genmab A/S has a consensus target price of $49.50, indicating a potential upside of 87.29%. Given Genmab A/S’s higher possible upside, analysts plainly believe Genmab A/S is more favorable than Organigram.

Summary

Genmab A/S beats Organigram on 11 of the 14 factors compared between the two stocks.

About Organization Chart

(Get a free report)

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. Offers medical cannabis products including whole flower, ground flower, pre-rolls, infused pre-rolls, vapes, gums and concentrates for medical retailers; adults use recreational cannabis under the brands SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED’ems, Edison Cannabis Co., Edison JOLTS, Tremblant and Laurentian. The company also engages in the wholesale transportation of cannabis plant cuttings, dried flowers, blends, pre-rolls and cannabis-derived products to adult recreational cannabis retailers and wholesalers. It sells its products through online as well as consumer channels. The company was founded in 2010 and is headquartered in Toronto, Canada.

About Genmab A/S

(Get a free report)

Genmab A/S develops antibody therapies for the treatment of cancer and other diseases, primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab for treating MM, non-MM and AL amyloidosis blood cancers; GEN1047; tisotumab vedotin to treat cervical, ovarian and solid cancer; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 to treat hematological malignancies. In addition, the company is developing Inclacumab, which is in phase 3 for vaso-occlusive crises; Camidanlumab tesirin for treating Hodgkin’s lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for the treatment of celiac disease; Mim8 for treating hemophilia A; and Lu AF82422 for the treatment of multiple system atrophy disease. It operates various active preclinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to jointly develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Get news and reviews for Organigram Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Organigram and related companies with MarketBeat.com’s FREE daily email newsletter.